4 - Cibus, Inc. (0001705843) (Issuer)

4 - Cibus, Inc. (0001705843) (Issuer)

4 - Cibus, Inc. (0001705843) (Issuer)

4 - Cibus, Inc. (0001705843) (Issuer)

4 - Cibus, Inc. (0001705843) (Issuer)

4 - Cibus, Inc. (0001705843) (Issuer)

4 - Cibus, Inc. (0001705843) (Issuer)

4 - Cibus, Inc. (0001705843) (Issuer)

4 - Cibus, Inc. (0001705843) (Issuer)

4 - Cibus, Inc. (0001705843) (Issuer)

EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

Cibus Announces Election of New Board Member, Deepening Strategic Leadership and Experience SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a global leader in Gene Editing in agriculture and the development of Productivity Traits in plants that directly impact farming productivity and profitability announced that its Board of Directors has elected Jim Collins, former CEO of Corteva, to the Board. "Jim brings to Cibus immense knowledge and strategic vision on the direction of the future role and use of Gene Editing in agriculture," said Mark Finn, Chair of the Audit Committee. "Jim's experience leading one of the largest agricultural and seed companies will gi

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, announced today the appointment of Steve Berreth as General Counsel and Corporate Secretary for the corporation. Mr. Berreth was previously Vice President, General Counsel and Secretary for Syngenta Crop Protection LLC, the North American Subsidiary of Syngenta AG, one of the world's largest biotechnology agribusinesses and one of the largest crop protection chemical and seed businesses in the world. He was a member of the Syngenta global legal and compliance leadership teams and led the North American le

EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, and Peter Beetham, Co-Founder, President, and Chief Operating Officer, will host a presentation at the Sidoti Micro Cap Conference. Presentation detailsDate: Thursday, January 23, 2025Time: 1:45 p.m. ET (10:45 a.m. PT)         Webcast link: https://sidoti.zoom.us/webinar/register/WN_zgpeW_rJSbS6UDdU4sskZQ About Cibus Cibus is a leader in gene edited produc

SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company" or "Cibus"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced it has entered into securities purchase agreements with existing investors of the Company, including institutional and strategic investors, as well as with the Company's CEO, Rory Riggs, for the purchase and sale of 9,040,000 shares of its Class A Common Stock (inclusive of pre-funded warrants to purchase shares of Class A Common Stock, in lieu of common stock), and warrants to purchase up to an aggregate of 9,040,

Culmination of Advances in Gene Editing Efficiency and Process Improvements Drives Standardization of Cibus' Gene Editing System Delivering Traits in a Customer's Elite Germplasm in less than 12 Months Cibus Announces Editing Milestone in the Continuing Development of its Soybean Platform SAN DIEGO, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that it has established production standards for its proprietary RTDS gene editing process. These standards, applicable to the Company's developed and advanced traits, represent the accom

Cibus' Rice Herbicide Tolerance (HT-3) Commercialization Efforts Continue Promising Progress to deliver a new Weed Management Solution for Farmers in the U.S. Cibus and its partners Albaugh and RTDC Continue Their Research and Development Collaboration to Enable Commercialization of Cibus' Clethodim-Tolerant HT-3 Rice Trait SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties announced an agreement affirming its collaboration with RTDC Corporation Limited and Albaugh LLC to provide Clethodim as part of Cibus' weed management solution for U.S. rice farm

Cibus and Biographica to collaborate on identifying gene editing targets for Cibus' disease resistance trait development Biographica's proprietary AI platform linked with Cibus' crop editing abilities provide opportunities for discovery and commercial application SAN DIEGO and LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, and Biographica, a UK-based leader in AI and graph machine learning for gene discovery, are pleased to announce a collaborative pilot project focused on advancing disease resistance in oilseed rape and Canola. This partnership

SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, will participate in the 13th Annual Roth Technology Conference. The conference is being held in New York City on November 19-20, 2024. Cibus is available for meetings on both days of the conference. Conference attendees should reach out to the Company or their conference host representative to schedule. About Cibus Cibus is a leading independent plant trait company that develops and licenses plant traits

Cibus has successfully made the edits in Canola associated with the Company's 4th mode of action for its White Mold (Sclerotinia) trait  Builds upon Cibus' progress with its Sclerotinia resistance trait in Canola after Field Trial results for its 2nd mode of action showed enhanced disease resistance SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that it has successfully completed edits in Canola for its 4th mode of action for its Sclerotinia resistance trait and expects greenhouse results in the first quarter of 2025.

Announced a strategic realignment to advance commercial opportunities, focusing resources on advancement of weed management platform (HT1 and HT3) for Rice, Pod Shatter Reduction in Canola, Sclerotinia resistance for Canola and Soybean, and on Soybean platform development Great progress in Rice as we execute on our agreements with four major seed company customers in the United States and Latin America, with germplasm received from all customers; completed successful field trials with HT3 in customer germplasm, as well as completed what the Company believes to be the first field trials for stacked gene-edited herbicide tolerance traits Also in Rice, signed an Agreement with RTDC Corporatio

The greenhouse results represent an important success milestone in the development of its second-generation of HT2 edited Canola Cibus expects to initiate seed bulk up for testing in fields in 2025 SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that its next generation edits for herbicide tolerance (HT2) in Canola have shown increased tolerance to the herbicide in greenhouse testing. With the achievement of this milestone, seed from these edited plants will be utilized to initiate larger scale field testing in the 2025 season. Reachi